BI Asset Management Fondsmaeglerselskab A S Buys 29,136 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

BI Asset Management Fondsmaeglerselskab A S lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 75.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,673 shares of the medical equipment provider's stock after purchasing an additional 29,136 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Intuitive Surgical were worth $33,516,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in Intuitive Surgical by 24.9% in the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock worth $1,916,000 after purchasing an additional 731 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its stake in Intuitive Surgical by 0.5% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock worth $99,678,000 after purchasing an additional 883 shares in the last quarter. MML Investors Services LLC boosted its stake in Intuitive Surgical by 0.4% in the 4th quarter. MML Investors Services LLC now owns 63,181 shares of the medical equipment provider's stock worth $32,978,000 after purchasing an additional 228 shares in the last quarter. Tradition Wealth Management LLC boosted its stake in Intuitive Surgical by 65.5% in the 4th quarter. Tradition Wealth Management LLC now owns 2,156 shares of the medical equipment provider's stock worth $1,125,000 after purchasing an additional 853 shares in the last quarter. Finally, TD Waterhouse Canada Inc. boosted its stake in Intuitive Surgical by 25.5% in the 4th quarter. TD Waterhouse Canada Inc. now owns 28,416 shares of the medical equipment provider's stock worth $14,831,000 after purchasing an additional 5,765 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

Insider Activity

In other news, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the sale, the executive vice president owned 353 shares of the company's stock, valued at $173,845.44. This represents a 92.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Gary S. Guthart sold 2,800 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $495.24, for a total transaction of $1,386,672.00. Following the sale, the insider directly owned 18,520 shares of the company's stock, valued at $9,171,844.80. The trade was a 13.13% decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,839 shares of company stock valued at $7,896,972 in the last quarter. 0.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ISRG. Evercore ISI upped their price target on shares of Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Wells Fargo & Company lifted their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a report on Wednesday, July 23rd. BTIG Research lifted their price objective on Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Erste Group Bank reiterated a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $595.00 price objective (up from $575.00) on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Thirteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $595.95.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded up $6.28 during midday trading on Friday, hitting $476.16. 2,023,902 shares of the company's stock traded hands, compared to its average volume of 1,973,062. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00. The stock has a market capitalization of $170.69 billion, a price-to-earnings ratio of 66.41, a price-to-earnings-growth ratio of 4.92 and a beta of 1.59. The firm has a fifty day moving average of $504.42 and a 200 day moving average of $522.06.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The firm had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. The business's revenue for the quarter was up 21.4% compared to the same quarter last year. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.